European E-Congress of Rheumatology 2020 (EULAR 2020)

TNFi use in RA tied to reduced VTE risk

Roshini Claire Anthony, 20200625140001

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.